You just read:

FDA grants orphan drug designation to Boehringer Ingelheim's investigational anti-CD33 monoclonal antibody BI 836858 for treatment of myelodysplastic syndromes

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Mar 09, 2017, 08:00 ET